A recent study of an mRNA vaccine in a mouse model of Clostridioides difficile infection provided proof of concept of a protective effect.
Van Andel Institute scientists and collaborators have developed a new method for identifying and classifying pancreatic cancer cell subtypes based on sugars found on the outside of cancer cells.
These sugars, called glycans, help cells recognize and communicate with each other. They also act as a cellular “signature,” with each subtype of pancreatic cancer cell possessing a different composition of glycans.
The new method, multiplexed glycan immunofluorescence, combines specialized software and imaging techniques to pinpoint the exact mix of pancreatic cancer cells that comprise tumors. In the future, this information may aid in earlier, more precise diagnosis.
The team at Omron Sinic X say that, by 2050, they hope their AI can conduct whole experiments independently of human scientists.
Reports of extraterrestrial beings, particularly the iconic “grey aliens,” have permeated modern folklore and ufology since the mid-20th century. These beings — typically described as small-statured humanoids with large, black almond-shaped eyes, diminutive noses and mouths, and grey skin — have become embedded in our cultural consciousness (Sagan, 1995). But what if these entities are not visitors from distant stars, but rather glimpses of our own evolutionary future? This essay explores a compelling hypothesis: that the grey aliens reported in countless encounters might be evolved or bio-engineered humans from our future, adapted specifically for subterranean existence following a global catastrophe.
Humanity stands at a crossroads of existential risk. Climate change, nuclear proliferation, biological warfare capabilities, and ecological collapse represent just a few of the potential calamities that could force a dramatic reshaping of human civilization (Bostrom, 2013). If surface conditions on Earth became inhospitable — whether through nuclear winter, extreme solar radiation following ozone depletion, or uninhabitable surface temperatures — surviving populations might be driven underground, initiating a profound evolutionary divergence.
“When faced with extinction-level threats, species often undergo rapid adaptation to secure their survival,” notes evolutionary biologist Dr. Elena Rodriguez (2022, p. 87). “Humans, with their capacity for technological intervention in their own biology, could potentially accelerate this process by orders of magnitude.”
Stargate SG1 (TV Program),Stargate Atlantis (TV Program),David Hewlett, Rodney McKay,actor,writer,director,father,son,parenting, Dad,family,stargate atlantis t…
Superconductivity is a quantum property of materials entailing an electrical resistance of zero at very low temperatures. In some materials, multiple electronic bands are known to contribute to the emergence of superconductivity, leading to multiple superconducting energy gaps. This phenomenon is referred to as multiband superconductivity.
Researchers at Lund University in Sweden, Institut Laue Langevin in France and other institutes in Europe recently carried out a study aimed at better understanding the multiband superconductivity emerging in the transition metal dichalcogenide 2H-NbSe2, which exhibits a vortex lattice when exposed to a magnetic field.
Their findings, published in Physical Review Letters, unveil two key contributions to the superconducting state observed in this material.
An investigation of the changing behaviour of a single quantum bit through time has uncovered a tantalising similarity to the geometry of three-dimensional space
Is Chief Executive Officer and Managing Director of Cynata Therapeutics (https://cynata.com/), a stem cell and regenerative medicine company that is known for its proprietary Cymerus platform, for the scalable and consistent production of mesenchymal stem cell (MSC)-based therapies.
Unlike traditional MSC therapies that rely on multiple donors, the Cymerus manufacturing process ensures that cells for therapeutic use can be produced in virtually limitless quantities from a single donor – making the opportunities endless and attractive from a manufacturing standpoint. The company has completed Phase I studies for Graft vs Host disease & Diabetic Foot Ulcers and have a number of Phase II, and even have a Phase III clinical trial, in progress.
Dr. Kelly has over 20 years’ experience in biopharmaceutical research and development, including almost 15 years focused on the development of mesenchymal stem cell (MSC) based therapies. He joined Cynata in March 2014, initially as Vice President, Product Development, then Chief Operating Officer from May 2019, and since July 2023 has been CEO & MD. At Cynata, he has overseen all stages of the development of the Cymerus induced pluripotent stem cell (iPSC)-derived MSC technology, including the first completed clinical trial of any iPSC-derived product worldwide.
Dr. Kelly previously held positions at Biota Pharmaceuticals, Mesoblast Limited, Kendle International, Amgen and AstraZeneca.
Dr. Kelly holds a Masters in Pharmacy degree from the Robert Gordon University, Aberdeen, a Ph.D. in Pharmaceutical Sciences from Strathclyde University, Glasgow, and he is a Graduate of the Australian Institute of Company Directors (AICD), Melbourne. He is a member of the International Society for Cell and Gene Therapy (ISCT), the International Society for Stem Cell Research (ISSCR), the Royal Pharmaceutical Society and the AICD.
Dr. Kelly also serves on the ISCT Asia-Pacific Industry Committee, the ISSCR Best Practices Working Group for the Development of PSC-Derived Therapies and the Industry Interface Committee of the Center for Commercialization of Regenerative Medicine (CCRM) Australia.